Collectively,these findings demonstrate the ability of ReSisTrace to unveil pre-existingtranscriptional features of treatment vulnerability in hematological cancers andelucidate strategies for enhancing FLT3 inhibitor treatment efficacy inFLT3-ITD-mutated AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.